NeuroVive Pharmaceutical - Capital markets day take aways
On 9 October 2019, NeuroVive held its capital markets day. Management presented its strategic focus on the company's primary mitochondrial disease...
1k Views
NeuroVive Pharmaceutical - Licensing deal and R&D pipeline progress
On 18 June 2018, NeuroVive announced that it had out-licensed a subset of compounds from its NVP015 programme (succinate prodrugs) to BridgeBio, a...
54 Views
NeuroVive Pharmaceutical - Rights issue to reach several R&D events
NeuroVive’s planned rights issue (subject to approval at the EGM) is expected to bring in a minimum guaranteed amount of at least SEK55m (gross),...
65 Views
NeuroVive Pharmaceutical - Two new trials and likely out-licensing in 2018
NeuroVive has made progress on multiple fronts over the past few months with both its core asset portfolio and non-core projects for out-licensing....
43 Views
R&D progress on track; new investor on board
NeuroVive’s recent Q217 report described R&D activities progressing according to plan. The company is preparing for the next clinical studies...
60 Views